Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
Boston Family Office LLC Trims Holdings in Abbott Laboratories $ABT
03:30am, Monday, 01'st Dec 2025
Boston Family Office LLC trimmed its holdings in Abbott Laboratories (NYSE: ABT) by 0.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange C
This Top Dividend King Just Became an Even Better Buy
02:05am, Sunday, 30'th Nov 2025
Abbott Laboratories is acquiring Exact Sciences, in a move that will help bolster its diagnostics business. Abbott should expand the reach of Exact Sciences' key products and fuel its innovative engin
Best Dividend Aristocrats For December 2025
08:02am, Saturday, 29'th Nov 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,
Balanced Wealth Group LLC Acquires 732 Shares of Abbott Laboratories $ABT
03:26am, Saturday, 29'th Nov 2025
Balanced Wealth Group LLC boosted its holdings in shares of Abbott Laboratories (NYSE: ABT) by 20.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securitie
Abbott Laboratories $ABT Stock Holdings Lifted by Bank of Nova Scotia Trust Co.
04:50am, Friday, 28'th Nov 2025
Bank of Nova Scotia Trust Co. lifted its holdings in shares of Abbott Laboratories (NYSE: ABT) by 16.8% in the second quarter, according to the company in its most recent filing with the Securities an
Abbott Laboratories $ABT Stake Lifted by Clarkston Capital Partners LLC
04:16am, Friday, 28'th Nov 2025
Clarkston Capital Partners LLC increased its position in shares of Abbott Laboratories (NYSE: ABT) by 15.1% during the undefined quarter, according to the company in its most recent Form 13F filing wi
Aviso Financial Inc. Has $4.83 Million Position in Abbott Laboratories $ABT
04:03am, Tuesday, 25'th Nov 2025
Aviso Financial Inc. grew its position in shares of Abbott Laboratories (NYSE: ABT) by 7.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commissi
Abbott issues US device correction for some glucose monitors over faulty readings risk
11:08am, Monday, 24'th Nov 2025
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some
Bank Julius Baer & Co. Ltd Zurich Boosts Stock Position in Abbott Laboratories $ABT
04:38am, Monday, 24'th Nov 2025
Bank Julius Baer and Co. Ltd Zurich raised its stake in Abbott Laboratories (NYSE: ABT) by 1.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commi
Boston Research & Management Inc. Reduces Holdings in Abbott Laboratories $ABT
04:46am, Sunday, 23'rd Nov 2025
Boston Research and Management Inc. lowered its position in Abbott Laboratories (NYSE: ABT) by 1.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of E
Top 2 Healthcare Stocks Every New Investor Should Know
08:15am, Friday, 21'st Nov 2025
These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.
2 Fantastic Dividend Stocks to Buy and Hold Forever
05:47am, Friday, 21'st Nov 2025
Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.
Abbott Labs Expands into Cancer Diagnostics with Exact Sciences Acquisition
12:14pm, Thursday, 20'th Nov 2025
Abbott Labs (ABT) has acquired Exact Sciences (EXAS) for $105 per share in cash, a 56% premium over the previous stock price, valuing EXAS at $21 billion, or ap
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
11:03am, Thursday, 20'th Nov 2025
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Scie
